Treatment of Bacterial Vaginosis: A Multicenter, Double-Blind, Double-Dummy, Randomised Phase III Study Comparing Secnidazole and Metronidazole

Table 3

Overall therapeutic success at D14.

	Population
	ITT	mITT	PPD14*
Secnidazole	62.4%	65.0%	68.7%
	(191/290)	(158/243)	(147/214)
Metronidazole	65.2%	66.2%	69.0%
	(187/287)	(157/237)	(149/216)
95% CI Secnidazole-Metronidazole	[−0.106; 0.051]	[−0.097; 0.073]	[−0.09; 0.085]

*PPD14 (per protocol population at day 14): patients who were assessable and presented no major deviation from the protocol at day 14 (214 patients in the metronidazole group and 216 patients in the secnidazole group).